
AIM Stock Forecast & Price Target
AIM Analyst Ratings
Bulls say
AIM ImmunoTech Inc. has demonstrated a strong positive trajectory in clinical data, with initial results from its Phase 2 studies indicating potential therapeutic benefits of Ampligen in treating both post-COVID conditions and metastatic colorectal cancer. The continuous generation of favorable data from these studies is expected to serve as significant catalysts for the company's stock performance. Furthermore, the focus on addressing unmet medical needs in cancers and viral diseases positions AIM ImmunoTech favorably within the immuno-pharma sector, potentially enhancing investor confidence and market interest.
Bears say
AIM ImmunoTech Inc. reported a net loss of $3.3 million, significantly exceeding both internal and consensus estimates, indicating greater financial strain than anticipated. The company is also facing substantial risks related to its balance sheet and liquidity, as well as challenges in demonstrating the safety and efficacy of its product candidates in clinical trials which could hinder regulatory approvals and commercialization efforts. Additionally, AIM ImmunoTech must navigate a competitive landscape and shifting investor sentiment, factors that could further diminish prospects for securing suitable reimbursement and achieving long-term financial stability.
This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.
AIM Analyst Forecast & Price Prediction
Start investing in AIM
Order type
Buy in
Order amount
Est. shares
0 shares